Advertisement

Context Therapeutics Inc. CNTX

Set alert

Price alert · CNTX

All alert types
0.19 USD -0.01 -6.25%

At close · Oct 30

0.19 0.00 +1.96%

After hours · Oct 30, 4:00 PM ET

Bid
0.19 × 3
Ask
0.19 × 3
0.1888 Day range 0.203
0.1891 52-week range 3.36
YTD
-87.14%
1 year
-83.27%
Open
0.203
Prev close
0.2017
Mkt cap
17.37M
Vol
1.01M
Avg vol
1.53M
EPS
-0.48
P/E
0.00
Div yield
0.00%
More statistics
Low
0.1888
High
0.203
Forward P/E
-3.38
Beta
2.25
Short ratio
2.79
Inst. own
76.40%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
1.79
200-d avg
1.86
1y target
7.70

MAX chart

Chart tools
Interval

Events in this range
  • Mar 21, 2024Earnings: —; estimate -0.35; surprise —%
  • May 8, 2024Earnings: -0.23; estimate -0.38; surprise 39.47%
  • May 8, 2024Earnings: —; estimate -0.38; surprise —%
  • May 9, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • May 16, 2024Rating: Piper Sandler · — → Overweight
  • Jul 10, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Aug 7, 2024Earnings: —; estimate -0.08; surprise —%
  • Aug 7, 2024Earnings: -0.04; estimate -0.08; surprise 50%
  • Sep 16, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Sep 23, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Nov 6, 2024Earnings: -0.22; estimate -0.11; surprise -100%
  • Nov 25, 2024Rating: D. Boral Capital · — → Buy
Signals (73)
NameDateAgo
MACD: Buy SignalOct 12, 20262 weeks ago
RSI: OversoldOct 12, 20262 weeks ago
SMA: BearishJun 1, 20265 months ago
SMA: BearishJun 1, 20265 months ago
SMA: BullishMay 18, 20265 months ago
MACD: Sell SignalApr 13, 20266 months ago
SMA: BearishApr 6, 20266 months ago
RSI: OverboughtMar 2, 20268 months ago
RSI: OverboughtJan 26, 20269 months ago
SMA: BullishDec 15, 202510 months ago
MACD: Buy SignalDec 15, 202510 months ago
MACD: Sell SignalDec 8, 202510 months ago
SMA: BearishNov 17, 202511 months ago
SMA: BullishAug 11, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BullishJul 14, 20251 year ago
SMA: BullishJul 7, 20251 year ago
SMA: BearishMay 12, 20251 year ago
MACD: Buy SignalApr 14, 20251 year ago
SMA: BullishApr 7, 20251 year ago
SMA: BearishNov 4, 20241 year ago
SMA: BearishNov 4, 20241 year ago
SMA: BullishOct 21, 20242 years ago
SMA: BearishSep 23, 20242 years ago
SMA: BearishSep 9, 20242 years ago
MACD: Sell SignalSep 9, 20242 years ago
SMA: BullishJul 8, 20242 years ago
SMA: BearishJul 1, 20242 years ago
RSI: OverboughtMay 13, 20242 years ago
SMA: BullishMar 18, 20242 years ago
SMA: BearishMar 11, 20242 years ago
SMA: BullishFeb 19, 20242 years ago
SMA: BullishFeb 19, 20242 years ago
MACD: Buy SignalFeb 19, 20242 years ago
SMA: BearishJan 22, 20242 years ago
MACD: Sell SignalJan 22, 20242 years ago
SMA: BullishJan 1, 20242 years ago
MACD: Buy SignalJan 1, 20242 years ago
SMA: BullishDec 18, 20232 years ago
SMA: BearishNov 6, 20232 years ago
SMA: BearishNov 6, 20232 years ago
MACD: Sell SignalNov 6, 20232 years ago
SMA: BullishOct 30, 20233 years ago
SMA: BullishOct 30, 20233 years ago
MACD: Buy SignalOct 30, 20233 years ago
SMA: BearishOct 23, 20233 years ago
SMA: BearishOct 23, 20233 years ago
MACD: Sell SignalOct 23, 20233 years ago
SMA: BullishSep 25, 20233 years ago
MACD: Buy SignalSep 25, 20233 years ago
SMA: BullishSep 11, 20233 years ago
SMA: BearishSep 4, 20233 years ago
MACD: Sell SignalAug 21, 20233 years ago
SMA: BearishJul 17, 20233 years ago
RSI: OverboughtJun 26, 20233 years ago
SMA: BullishMay 22, 20233 years ago
SMA: BullishMay 15, 20233 years ago
SMA: BearishFeb 27, 20233 years ago
SMA: BullishJan 30, 20233 years ago
MACD: Buy SignalJan 23, 20233 years ago
MACD: Sell SignalDec 19, 20223 years ago
SMA: BearishDec 5, 20223 years ago
RSI: OversoldDec 5, 20223 years ago
SMA: BullishNov 14, 20223 years ago
MACD: Buy SignalOct 31, 20224 years ago
MACD: Sell SignalOct 3, 20224 years ago
RSI: OversoldSep 12, 20224 years ago
SMA: BearishAug 15, 20224 years ago
SMA: BullishAug 8, 20224 years ago
SMA: BearishJul 18, 20224 years ago
SMA: BullishMay 23, 20224 years ago
SMA: BearishApr 11, 20224 years ago
SMA: BullishMar 14, 20224 years ago

Key statistics

Market cap
73.50M
Enterprise value
64.96M
Trailing P/E
0.00
Forward P/E
-3.38
PEG ratio
0.00
Price / sales
0.00
Price / book
1.32
EPS (TTM)
-0.88
Beta
2.25
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-12.33M
Total cash
101.54M
Total debt
0
Return on equity
-29.68%
Shares outstanding
75.00M
Short % of float
1.54%
50-day average
1.79
200-day average
1.86

Analyst view

Consensus: none

Price target (mean) 7.70 +3971.9% upside
Target (low)
4.50
Target (mean)
7.70
Target (high)
10.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy2
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 7, 2024

Expected Aug 7, 2024. Consensus EPS estimate -0.05.

Earnings history

Financials — quick view

All financials
CNTX Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CNTX Net income — quarterly -14.56M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CNTX EPS — quarterly -0.15
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CNTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.11-0.22-0.11-100.00%
Aug 7, 2024Jun 1, 2024-0.08———
Aug 7, 2024Jun 1, 2024-0.08-0.04+0.04+50.00%
May 8, 2024Mar 1, 2024-0.38-0.23+0.15+39.47%
May 8, 2024Mar 1, 2024-0.38———
Mar 21, 2024Dec 1, 2023-0.35———

Upgrades / downgrades

CNTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 25, 2024D. Boral Capitalinit—Buy
Sep 23, 2024HC Wainwright & Co.reitBuyBuy
Sep 16, 2024HC Wainwright & Co.reitBuyBuy
Jul 10, 2024HC Wainwright & Co.reitBuyBuy
May 16, 2024Piper Sandlerinit—Overweight
May 9, 2024HC Wainwright & Co.mainBuyBuy

About Context Therapeutics Inc.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on CNTX — it syncs with the Stock Master app.

Insider holders

CNTX insider holders
InsiderRelationLatest transactionDateShares held
LEHR MARTIN AChief Executive OfficerPurchaseFeb 20, 2023979,891

Institution ownership

CNTX institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp9.89%7,419,3557.27MSep 29, 2024
Nextech Invest Ag9.89%7,419,3557.27MSep 29, 2024
Avidity Partners Management, LP9.89%7,417,1557.27MSep 29, 2024
Great Point Partners LLC9.25%6,934,9826.80MSep 29, 2024
Blue Owl Capital Holdings LP7.22%5,411,2905.30MSep 29, 2024
Vanguard Group Inc4.99%3,744,9613.67MSep 29, 2024

Fund ownership

CNTX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund4.17%3,124,4003.06MSep 29, 2024
Vanguard Extended Market Index Fund0.74%554,824543.73KSep 29, 2024
Fidelity Extended Market Index Fund0.39%295,078289.18KOct 30, 2024
Fidelity Total Market Index Fund0.13%99,06197.08KOct 30, 2024
Fidelity Series Total Market Index Fund0.09%69,66568.27KOct 30, 2024
Vanguard Institutional Index-Inst Total Stock Market Ind0.07%53,12552.06KSep 29, 2024
Advertisement